MedDataX Logo

Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma

NCT ID: NCT00406900

Last Updated: 2006-12-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

560 participants

Study Classification

OBSERVATIONAL

Study Start Date

1999-01-31

Study Completion Date

2006-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Uveal Melanoma is the most common primary intraocular tumor in adults. Most tumors metastasize to the liver. So far no sensitive or specific serological tumor marker is routinely used. The marker "Melanoma inhibitory activity" is a promising marker. Study hypothesis is to detect metastatic lesions in an early stage. This would increase life expectance of our patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Serum is taken from each melanoma patient at every follow up after signed concent. With ELISA the marker MIA is evaluated. An increase of MIA serum level will lead to search for metastasis by oncologists.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melanoma Radiotherapy Metastatic Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

uveal melanoma metastatic disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

DEFINED_POPULATION

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Treatment of metastatic disease

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* uveal melanoma (With/without overt metastatic disease)
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ludwig-Maximilians - University of Munich

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ulrich C Schaller, MD

Role: PRINCIPAL_INVESTIGATOR

University of Munich, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dept of Ophthalmology, University of Munich

Munich, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ulrich C Schaller, MD

Role: CONTACT

Phone: +49/89/5160

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ulrich C Schaller, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Schaller UC, Bosserhoff AK, Neubauer AS, Buettner R, Kampik A, Mueller AJ. Melanoma inhibitory activity: a novel serum marker for uveal melanoma. Melanoma Res. 2002 Dec;12(6):593-9. doi: 10.1097/01.cmr.0000043146.28051.b8.

Reference Type RESULT
PMID: 12459649 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MIA

Identifier Type: -

Identifier Source: org_study_id